Pharmaco-proteogenomic profiling of pediatric diffuse midline glioma to inform future treatment strategies

A pilot radiogenomic study of DIPG reveals distinct subgroups with unique clinical trajectories and therapeutic targets

(2021) Xiaoting Zhu et al.   Acta Neuropathologica Communications

World Cancer Day 2021 - Perspectives in Pediatric and Adult Neuro-Oncology

(2021) Erik P. Sulman et al.   Frontiers in Oncology

The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

(2021) David N Louis et al.   NEURO-ONCOLOGY

The H3K36me2 writer-reader dependency in H3K27M-DIPG

(2021) Jia-Ray Yu et al.   Science Advances

First-in-human Phase I study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma

(2020) Patrick Y. Wen et al.   CLINICAL CANCER RESEARCH

Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG

(2020) Anatoly Nikolaev et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

An Update on Neurofibromatosis Type 1-Associated Gliomas

(2020) Lobbous et al.   Cancers

Invaders Exposed: Understanding and Targeting Tumor Cell Invasion in Diffuse Intrinsic Pontine Glioma

(2020) T. A. Kluiver et al.   Frontiers in Oncology

Histone H3 wild-type DIPG/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation

(2020) David Castel et al.   ACTA NEUROPATHOLOGICA

Pharmacokinetics, safety and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

(2020) Catherine Hanna et al.   NEURO-ONCOLOGY

Global activation of oncogenic pathways underlies therapy resistance in diffuse midline glioma

(2020) M.-M. Georgescu et al.   Acta Neuropathologica Communications

Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia

(2020) Heather C. Murray et al.   LEUKEMIA

H3 K27M and EZHIP Impede H3K27-Methylation Spreading by Inhibiting Allosterically Stimulated PRC2

(2020) Siddhant U. Jain et al.   MOLECULAR CELL

Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer

(2020) Marie Wong et al.   NATURE MEDICINE

Combined treatment with CBP and BET inhibitors reverses inadvertent activation of detrimental super enhancer programs in DIPG cells

(2020) Maria Wiese et al.   Cell Death & Disease

Integrated Proteogenomic Characterization across Major Histological Types of Pediatric Brain Cancer

(2020) Francesca Petralia et al.   CELL

Epigenetic activation of a RAS/MYC axis in H3.3K27M-driven cancer

(2020) Sanja Pajovic et al.   Nature Communications

ACVR1 R206H cooperates with H3.1K27M in promoting diffuse intrinsic pontine glioma pathogenesis

(2019) Christine M. Hoeman et al.   Nature Communications

Inhibition of mutant PPM1D enhances DNA damage response and growth suppressive effects of ionizing radiation in diffuse intrinsic pontine glioma

(2019) Mwangala Precious Akamandisa et al.   NEURO-ONCOLOGY

H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo

(2019) André B. Silveira et al.   ACTA NEUROPATHOLOGICA

Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience

(2019) Elke Pfaff et al.   EUROPEAN JOURNAL OF CANCER

The EMBL-EBI search and sequence analysis tools APIs in 2019

(2019) Fábio Madeira et al.   NUCLEIC ACIDS RESEARCH

Protein synthesis rates and ribosome occupancies reveal determinants of translation elongation rates

(2019) Andrea Riba et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Signal Transduction in Diffuse Intrinsic Pontine Glioma

(2019) Ryan J. Duchatel et al.   PROTEOMICS

TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)

(2019) Coralie Werbrouck et al.   CLINICAL CANCER RESEARCH

Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma

(2019) Chul-Hwan Lee et al.   GENES & DEVELOPMENT

Omomyc reveals new mechanisms to inhibit the MYC oncogene

(2019) Mark J. Demma et al.   MOLECULAR AND CELLULAR BIOLOGY

Electrical and synaptic integration of glioma into neural circuits

(2019) Humsa S. Venkatesh et al.   NATURE

The Role of Reactive Oxygen Species in Acute Myeloid Leukaemia

(2019) Sillar et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening

(2019) Grant L. Lin et al.   Science Translational Medicine

Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas

(2018) Sharmistha Pal et al.   CANCER RESEARCH

MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer

(2018) Renée de Leeuw et al.   CLINICAL CANCER RESEARCH

Emerging therapeutic targets for neurofibromatosis type 1

(2018) James A. Walker et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG Registries

(2018) Lindsey M. Hoffman et al.   JOURNAL OF CLINICAL ONCOLOGY

Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells

(2018) Mara Vinci et al.   NATURE MEDICINE

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

(2018) Qiang Zhang et al.   Cell Death & Disease

Immune Microenvironment in Glioblastoma Subtypes

(2018) Zhihong Chen et al.   Frontiers in Immunology

Suppression of insulin feedback enhances the efficacy of PI3K inhibitors

(2018) Benjamin D. Hopkins et al.   NATURE

Virtual screening using covalent docking to find activators for G245S mutant p53

(2018) Sara Ibrahim Omar et al.   PLoS One

The germline genetic component of drug sensitivity in cancer cell lines

(2018) Michael P. Menden et al.   Nature Communications

Histone H3.3 K27M Accelerates Spontaneous Brainstem Glioma and Drives Restricted Changes in Bivalent Gene Expression

(2018) Jon D. Larson et al.   CANCER CELL

CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors

(2018) Francesco Schettini et al.   Frontiers in Oncology

Integrating Pharmacoproteomics into Early-Phase Clinical Development: State-of-the-Art, Challenges, and Recommendations

(2017) Savita Nandal et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Tumor Microenvironment and Differential Responses to Therapy

(2017) Eishu Hirata et al.   Cold Spring Harbor Perspectives in Medicine

Genomic Insights into Diffuse Intrinsic Pontine Glioma

(2017) Danielle H. Lapin et al.   Frontiers in Oncology

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in Neuroblastoma

(2016) Lori S. Hart et al.   CLINICAL CANCER RESEARCH

The Silencing of CCND2 by Promoter Aberrant Methylation in Renal Cell Cancer and Analysis of the Correlation between CCND2 Methylation Status and Clinical Features

(2016) Lu Wang et al.   PLoS One

Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma

(2016) Hamid Nikbakht et al.   Nature Communications

Precision medicine: from pharmacogenomics to pharmacoproteomics

(2016) Allison B. Chambliss et al.   Clinical Proteomics

Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics

(2016) Lindsey M. Hoffman et al.   Acta Neuropathologica Communications

Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes

(2015) David Castel et al.   ACTA NEUROPATHOLOGICA

Disrupting NOTCH Slows Diffuse Intrinsic Pontine Glioma Growth, Enhances Radiation Sensitivity, and Shows Combinatorial Efficacy With Bromodomain Inhibition

(2015) Isabella C. Taylor et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Proteotranscriptomic Profiling of 231-BR Breast Cancer Cells: Identification of Potential Biomarkers and Therapeutic Targets for Brain Metastasis

(2015) Matthew D. Dun et al.   MOLECULAR & CELLULAR PROTEOMICS

Functionally defined therapeutic targets in diffuse intrinsic pontine glioma

(2015) Catherine S Grasso et al.   NATURE MEDICINE

Germline Mutations in Predisposition Genes in Pediatric Cancer

(2015) Jinghui Zhang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pathology, Molecular Genetics, and Epigenetics of Diffuse Intrinsic Pontine Glioma

(2015) Pawel Buczkowicz et al.   Frontiers in Oncology

Use of dexamethasone in patients with high-grade glioma: a clinical practice guideline

(2014) X. Kostaras et al.   Current Oncology

Strategy for “Detoxification” of a Cancer-Derived Histone Mutant Based on Mapping Its Interaction with the Methyltransferase PRC2

(2014) Zachary Z. Brown et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma

(2014) Gang Wu et al.   NATURE GENETICS

Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations

(2014) Pawel Buczkowicz et al.   NATURE GENETICS

Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma

(2014) Kathryn R Taylor et al.   NATURE GENETICS

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma

(2014) Adam M Fontebasso et al.   NATURE GENETICS

EGFR and c-Met Cross Talk in Glioblastoma and Its Regulation by Human Cord Blood Stem Cells

(2014) Kiran Kumar Velpula et al.   Translational Oncology

Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas

(2013) B. S. Paugh et al.   CANCER RESEARCH

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma

(2013) K. E. Sheppard et al.   CLINICAL CANCER RESEARCH

Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next-Generation Sequencing Era

(2013) N K Gillis et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression

(2013) K.-M. Chan et al.   GENES & DEVELOPMENT

Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma

(2013) P. W. Lewis et al.   SCIENCE

Phosphatases in SMAD regulation

(2012) David L. Bruce et al.   FEBS LETTERS

Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer

(2012) Elise Ruark et al.   NATURE

The double face of the histone variant H3.3

(2011) Emmanuelle Szenker et al.   CELL RESEARCH

The tumor microenvironment and its role in promoting tumor growth

(2008) T L Whiteside   ONCOGENE